JP2022537158A5 - - Google Patents

Info

Publication number
JP2022537158A5
JP2022537158A5 JP2021573841A JP2021573841A JP2022537158A5 JP 2022537158 A5 JP2022537158 A5 JP 2022537158A5 JP 2021573841 A JP2021573841 A JP 2021573841A JP 2021573841 A JP2021573841 A JP 2021573841A JP 2022537158 A5 JP2022537158 A5 JP 2022537158A5
Authority
JP
Japan
Prior art keywords
alkyldiyl
peg
pep
heteroaryl
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021573841A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537158A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/037477 external-priority patent/WO2020252294A1/en
Publication of JP2022537158A publication Critical patent/JP2022537158A/ja
Publication of JP2022537158A5 publication Critical patent/JP2022537158A5/ja
Priority to JP2025076031A priority Critical patent/JP2025118748A/ja
Ceased legal-status Critical Current

Links

JP2021573841A 2019-06-13 2020-06-12 アミノベンズアゼピン化合物、イムノコンジュゲート、及びそれらの使用 Ceased JP2022537158A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025076031A JP2025118748A (ja) 2019-06-13 2025-05-01 アミノベンズアゼピン化合物、イムノコンジュゲート、及びそれらの使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962861139P 2019-06-13 2019-06-13
US62/861,139 2019-06-13
US202062963884P 2020-01-21 2020-01-21
US62/963,884 2020-01-21
PCT/US2020/037477 WO2020252294A1 (en) 2019-06-13 2020-06-12 Aminobenzazepine compounds, immunoconjugates, and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025076031A Division JP2025118748A (ja) 2019-06-13 2025-05-01 アミノベンズアゼピン化合物、イムノコンジュゲート、及びそれらの使用

Publications (2)

Publication Number Publication Date
JP2022537158A JP2022537158A (ja) 2022-08-24
JP2022537158A5 true JP2022537158A5 (cg-RX-API-DMAC7.html) 2023-06-16

Family

ID=71608047

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021573841A Ceased JP2022537158A (ja) 2019-06-13 2020-06-12 アミノベンズアゼピン化合物、イムノコンジュゲート、及びそれらの使用
JP2025076031A Pending JP2025118748A (ja) 2019-06-13 2025-05-01 アミノベンズアゼピン化合物、イムノコンジュゲート、及びそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025076031A Pending JP2025118748A (ja) 2019-06-13 2025-05-01 アミノベンズアゼピン化合物、イムノコンジュゲート、及びそれらの使用

Country Status (12)

Country Link
US (2) US20200390899A1 (cg-RX-API-DMAC7.html)
EP (1) EP3983082A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022537158A (cg-RX-API-DMAC7.html)
KR (1) KR20220034784A (cg-RX-API-DMAC7.html)
CN (1) CN114585390A (cg-RX-API-DMAC7.html)
AU (1) AU2020291014B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021025034A2 (cg-RX-API-DMAC7.html)
CA (1) CA3142887A1 (cg-RX-API-DMAC7.html)
IL (1) IL288816A (cg-RX-API-DMAC7.html)
MX (1) MX2021015221A (cg-RX-API-DMAC7.html)
TW (1) TW202112752A (cg-RX-API-DMAC7.html)
WO (1) WO2020252294A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019000071A2 (pt) 2016-07-07 2019-07-02 Bolt Biotherapeutics Inc conjugados adjuvantes de anticorpo
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
EP4038053A1 (en) * 2019-09-30 2022-08-10 Bolt Biotherapeutics, Inc. Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
EP4048315B1 (en) 2019-10-25 2025-03-12 Bolt Biotherapeutics, Inc. Thienoazepine immunoconjugates, and uses thereof
JP2023511362A (ja) 2020-01-21 2023-03-17 ボルト バイオセラピューティクス、インコーポレーテッド 坑pd-l1抗体
US11179473B2 (en) 2020-02-21 2021-11-23 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
CA3176626A1 (en) * 2020-05-08 2021-11-11 David Dornan Elastase-substrate, peptide linker immunoconjugates, and uses thereof
KR20230047361A (ko) 2020-07-01 2023-04-07 아르스 파마슈티컬스 인크. 항-asgr1 항체 접합체 및 이의 용도
MX2023001679A (es) * 2020-08-13 2023-02-22 Bolt Biotherapeutics Inc Inmunoconjugados de pirazolazepina y usos de estos.
WO2022082030A2 (en) 2020-10-15 2022-04-21 Gritstone Bio, Inc. Antigen-binding proteins and related methods of use
US20220195066A1 (en) * 2020-12-11 2022-06-23 Bolt Biotherapeutics, Inc. Anti-cea immunoconjugates, and uses thereof
WO2022125891A2 (en) * 2020-12-11 2022-06-16 Bolt Biotherapeutics, Inc. Anti-cea immunoconjugates, and uses thereof
JP2023552790A (ja) * 2020-12-11 2023-12-19 ボルト バイオセラピューティクス、インコーポレーテッド 抗pd-l1イムノコンジュゲート、及びそれらの使用
JP2023552791A (ja) * 2020-12-11 2023-12-19 ボルト バイオセラピューティクス、インコーポレーテッド 抗her2免疫複合体、及びその使用
CA3200056A1 (en) * 2020-12-11 2022-06-16 Shelley Erin ACKERMAN Anti-her2 immunoconjugates, and uses thereof
WO2022155503A1 (en) * 2021-01-14 2022-07-21 Gritstone Bio, Inc. Multi-specific antibodies and methods of use
CN117940168A (zh) * 2021-03-26 2024-04-26 博尔特生物治疗药物有限公司 2-氨基-4-甲酰胺-苯并氮杂䓬免疫缀合物及其用途
CN117769439A (zh) * 2021-03-26 2024-03-26 博尔特生物治疗药物有限公司 2-氨基-4-甲酰胺-苯并氮杂卓免疫缀合物及其用途
EP4342884A4 (en) * 2021-05-19 2025-10-29 Shanghai De Novo Pharmatech Co Ltd Compound containing nitrogen, conjugate containing said compound, and associated use
US20250057967A2 (en) * 2021-06-25 2025-02-20 Bolt Biotherapeutics, Inc. Bis-benzimidazole sting agonist immunoconjugates, and uses thereof
US20250000995A1 (en) 2021-10-29 2025-01-02 Bolt Biotherapeutics, Inc. Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof
EP4450496A4 (en) * 2021-12-16 2025-12-24 Duality Biologics Suzhou Co Ltd TLR MODULATOR AND ITS USAGE
WO2023154302A1 (en) * 2022-02-09 2023-08-17 Bolt Biotherapeutics, Inc. Macromolecule-supported 8-sulfonyl-benzazepine compounds and their uses
TW202339806A (zh) * 2022-02-09 2023-10-16 美商博特生物治療公司 8—磺醯基—苯并氮呯免疫結合物及其用途
WO2023232142A1 (zh) * 2022-06-02 2023-12-07 映恩生物制药(苏州)有限公司 一种药物化合物及其用途
WO2024173387A1 (en) 2023-02-14 2024-08-22 Bolt Biotherapeutics, Inc. Aza-benzazepine immunoconjugates, and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US723288A (en) 1901-10-26 1903-03-24 Harry South Lewis Cipher-key for cryptographic codes.
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
ATE370961T1 (de) 1998-05-06 2007-09-15 Genentech Inc Reinigung von antikörpern durch ionenaustauschchromatographie
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
AU5345901A (en) 2000-04-13 2001-10-30 Univ Rockefeller Enhancement of antibody-mediated immune responses
WO2005086875A2 (en) 2004-03-11 2005-09-22 City Of Hope A humanized anti-cea t84.66 antibody and uses thereof
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
NZ569204A (en) 2005-12-21 2012-03-30 Micromet Ag Pharmaceutical compositions with resistance to soluble CEA - comprising antibodies that bind to CD3 and CEA
PE20090245A1 (es) 2007-05-08 2009-03-17 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos
BRPI0818780A2 (pt) 2007-10-19 2015-04-22 Genentech Inc Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos
CN105669553A (zh) * 2009-08-18 2016-06-15 文蒂雷克斯药品公司 作为toll样受体调节剂的取代的苯并氮杂*
JP5845899B2 (ja) 2010-02-04 2016-01-20 東レ株式会社 癌の治療及び/又は予防用医薬組成物
EP2640727B1 (en) 2010-11-17 2015-05-13 Genentech, Inc. Alaninyl maytansinol antibody conjugates
KR101981342B1 (ko) 2011-03-02 2019-05-22 로슈 글리카트 아게 Cea 항체
KR101968499B1 (ko) 2011-08-04 2019-04-12 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
ES2672695T3 (es) 2011-08-04 2018-06-15 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la profilaxis del cáncer
CN103764825B (zh) 2011-08-04 2015-09-02 东丽株式会社 癌的治疗和/或预防用药物组合物
MX348579B (es) 2011-08-04 2017-06-20 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
AU2013223143B2 (en) 2012-02-21 2017-12-21 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
MX357505B (es) 2012-02-21 2018-07-12 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
IN2014KN01714A (cg-RX-API-DMAC7.html) 2012-02-21 2015-10-23 Toray Industries
ES2739380T3 (es) 2012-02-21 2020-01-30 Toray Industries Composición farmacéutica para el tratamiento del cáncer
WO2014014082A1 (ja) 2012-07-19 2014-01-23 東レ株式会社 癌の検出方法
CA2879185C (en) 2012-07-19 2021-08-24 Toray Industries, Inc. Method for detecting cancer
PT3199552T (pt) 2012-11-20 2020-03-25 Sanofi Sa Anticorpos anti-ceacam5 e suas utilizações
CA2918989C (en) 2013-08-09 2021-11-02 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
HRP20210977T1 (hr) 2014-02-10 2021-09-17 Merck Patent Gmbh Ciljano inhibiranje tgf beta
JP6805142B2 (ja) 2014-11-21 2020-12-23 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Cd73に対する抗体およびその使用
EP3233835B1 (en) * 2014-12-18 2019-01-23 F.Hoffmann-La Roche Ag Benzazepine sulfonamide compounds
HUE042563T2 (hu) * 2015-03-06 2019-07-29 Hoffmann La Roche Benzazepin-dikarboxamid vegyületek
MX383893B (es) * 2015-11-02 2025-03-14 Ventirx Pharmaceuticals Inc Uso de agonistas del receptor tipo toll- 8 (tlr8) para tratar el cáncer.
EP3464274B1 (en) * 2016-05-23 2020-05-27 H. Hoffnabb-La Roche Ag Benzazepine dicarboxamide compounds with secondary amide function
WO2017202704A1 (en) * 2016-05-23 2017-11-30 F. Hoffmann-La Roche Ag Benzazepine dicarboxamide compounds with tertiary amide function
EP3468963B1 (en) * 2016-06-12 2021-10-27 F. Hoffmann-La Roche AG Dihydropyrimidinyl benzazepine carboxamide compounds
WO2018079740A1 (ja) 2016-10-28 2018-05-03 東レ株式会社 癌の治療及び/又は予防用医薬組成物
CA3049791A1 (en) * 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
AU2018236272B2 (en) * 2017-03-15 2022-03-31 Silverback Therapeutics, Inc. Benzazepine compounds, conjugates, and uses thereof
WO2019084060A1 (en) * 2017-10-24 2019-05-02 Silverback Therapeutics, Inc. CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
CA3084667A1 (en) * 2017-12-15 2019-06-20 Silverback Therapeutics, Inc. Antibody construct-drug conjugate for the treatment of hepatitis
EP3849971A2 (en) * 2018-09-12 2021-07-21 Silverback Therapeutics, Inc. Substituted benzazepine compounds, conjugates, and uses thereof
WO2020056194A1 (en) * 2018-09-12 2020-03-19 Silverback Therapeutics, Inc. Benzazepine compounds, conjugates, and uses thereof
SG11202101980VA (en) * 2018-09-12 2021-03-30 Silverback Therapeutics Inc Methods and composition for the treatment of disease with immune stimulatory conjugates

Similar Documents

Publication Publication Date Title
JP2022553702A5 (cg-RX-API-DMAC7.html)
JP2022549510A5 (cg-RX-API-DMAC7.html)
JP2023002615A5 (cg-RX-API-DMAC7.html)
TWI851552B (zh) 磷脂醯肌醇蛋白聚醣(glypican)3抗體及其結合物
RU2503687C2 (ru) Сшивающие реагенты и их применение
JP2023547323A5 (cg-RX-API-DMAC7.html)
JP2024545233A5 (cg-RX-API-DMAC7.html)
JP2023524271A5 (cg-RX-API-DMAC7.html)
JP2022512778A5 (cg-RX-API-DMAC7.html)
JP2019520352A5 (cg-RX-API-DMAC7.html)
US20230295346A1 (en) Prodruggable antibodies, prodrugs thereof, and methods of use and making
JP2024546497A5 (cg-RX-API-DMAC7.html)
JP2019532056A5 (cg-RX-API-DMAC7.html)
JP2017518304A5 (cg-RX-API-DMAC7.html)
JP2024523453A5 (cg-RX-API-DMAC7.html)
JP2018516243A5 (cg-RX-API-DMAC7.html)
RU2018119296A (ru) Конъюгаты антитела, содержащие агонисты толл-подобного рецептора
JP2023553421A5 (ja) 抗cea免疫複合体、及びその使用
JP2024521921A5 (cg-RX-API-DMAC7.html)
JP2018511628A5 (cg-RX-API-DMAC7.html)
JP2020531471A5 (cg-RX-API-DMAC7.html)
JP2021527640A5 (cg-RX-API-DMAC7.html)
JP2022514949A5 (cg-RX-API-DMAC7.html)
JP2022546110A5 (cg-RX-API-DMAC7.html)
JP2025183307A5 (cg-RX-API-DMAC7.html)